Evidence map›Paper›PMID 40531412›Full record

ArticleProbiotics and antimicrobial proteins2026

Probiotics Ameliorate Histological Alterations and Prevent Increases in Cytokine and Toxin Levels in Mice Infected with Various Clostridioides difficile Strains.

Zohar Hamo, Hen Ninio, Maya Azrad, Dana Binyamin, Mor Zigdon, Halim Roshrosh, Avi Peretz

Abstract read
In one paragraph

Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zohar HamoAzrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Hen NinioClinical Microbiology Laboratory, Tzafon Medical Center, Poriya, Israel, Affiliated With Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Maya AzradClinical Microbiology Laboratory, Tzafon Medical Center, Poriya, Israel, Affiliated With Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Dana BinyaminAzrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Mor ZigdonAzrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Halim RoshroshClinical Microbiology Laboratory, Tzafon Medical Center, Poriya, Israel, Affiliated With Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Avi PeretzAzrieli Faculty of Medicine, Bar Ilan University, Safed, Israel. Aperetz@tzmc.gov.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severity of C. difficile infection (CDI) varies and can be influenced by bacterial strain, toxin levels, and antibiotic treatment. Current treatments are limited due to high recurrence rates and potential risks. This study aimed to characterize the manifestations of CDIs induced by various bacterial strains in mice and to assess the effects of different probiotic strains on these manifestations, with a focus on intestinal alterations, immune response, and toxin concentrations. The tested C. difficile strains induced significant intestinal damage and disrupted intestinal epithelial integrity, as indicated by reduced ZO-1 levels, with responses varying across strains. In addition, IL-6, TNF-α, and secreted toxin levels varied across the animal groups, with the highest levels seen in mice infected with sequence type 42 or 104. Administration of Lactobacillus acidophilus, Bifidobacterium bifidum, or Lactobacillus paracasei following CDI induction reduced intestinal damage, with the degree of rescue varying between probiotic strains. Lactobacillus paracasei demonstrated the most notable potential in alleviating CDI, marking its potential as an adjunct to conventional therapies for CDI.

Indexed as

Bacterial ToxinsClostridioides difficileClostridium InfectionsCytokinesProbioticsAnimalsBifidobacterium bifidumFemaleIntestinal MucosaLacticaseibacillus paracaseiLactobacillusLactobacillus acidophilusMaleMiceBacterial ToxinsCytokinesBifidobacterium bifidumClostridioides difficileEpithelial integrityIntestinal damageLactobacillus acidophilusLactobacillus paracasei

Identifiers

PMID40531412
PMCPMC13013258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.